リウマチ病セミナー　XXI　2010

出版社： 永井書店
著者：
発行日： 2010-12-25
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784815918729
シリーズ： リウマチ病セミナー
電子書籍版： 2010-12-25 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

リウマチ学のいまを知らせる好著．本セミナーは，1990年以来毎年発行されて，今回で21冊目。内容は，リウマチ病の捉え方に大きく影響する新しい知見とそれに基づく新しい考え方。リウマトロジーの醍醐味を教えてくれるリウマチ病研究の歴史。そして，今やリウマチ学の最大のテーマである骨粗鬆症の最新知見。多彩で新しい薬剤のレビュー，大きく進歩する手術技術などを取り上げる。

目次

  • リウマチ病セミナー　XXI　2010

    ―目次―

    炎症リウマチ
    　関節リウマチの寛解基準
    　Inflammageing（炎症性老化・加齢）と関節リウマチ
    　　?われわれは，環境からの攻撃による穏やかな慢性炎症に
    　　包まれて老いていくのか？?
    　ASの病態に関する新知見
    「炎症病態」からみた若年性特発性関節炎
    　強皮症2009
    　腎性全身性線維症（NSF：Nephrogenic systemic fibrosis）
    　自己炎症症候群
    　リウマチ病とアルコール
    　肺高血圧症2009
    　脊髄サルコイドーシス

    骨関節，脊椎，神経
    　大腿骨頭壊死と脂肪細胞
    　サッカーとスポーツ傷害
    　星状神経節の臨床
    　　?温故知新：“健康とは”からアプローチする全人的ケア?

    燐・カルシウム代謝
    　骨粗鬆症の新しい治療薬
    　ビスフォスフォネートに関連した顎骨壊死
    　骨折リスクの評価

    検査，評価
    　生活習慣・QOLの測定法
    　RAおよびASにおけるMMP3測定の有用性

    生物学的反応
    　AdipocytokineとOA
    　脳とリウマチ病
    　脂質メディエーター・スフィンゴシン１リン酸を標的とした
    　　新しい関節リウマチ治療薬の開発

    治療と副作用
    　生物学的製剤と感染症
    　生物学的製剤Up-date
    　IL?6阻害によるAAアミロイドーシスの新規治療
    　Imatinib
    　リウマチの痛みと鎮痛補助薬
    　　?Anticonvulsants（抗てんかん薬）と抗うつ薬?
    　線維筋痛症（FM）の新しい治療薬
    　ボツリヌスtoxinの臨床応用
    　炎症リウマチ治療中のワクチン接種

    手　　　術
    　母指CM関節（手根中手関節）の手術

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.9 掲載の参考文献
1) Aletaha D, Neogi T, Silman A, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010;62: 2569-2581.
PubMed
2) 塩沢俊一. 関節破壊機序と転写因子c-Fos/AP-1阻害薬, リウマチ病セミナーXX (七川歡次監修). 2010, p155-164, 大阪, 永井書店.
 
3) Aikawa Y, Morimoto K, Yamamoto T, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008: 26: 817-823.
PubMed
4) Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): arandomized, double-blind, parallel treatment trial. Lancet 2008;372: 375-382.
 
5) Pinals RS, Masi AT, Larsen RA et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24: 1308-1315.
PubMed
6) Sesin CA, Bingham CO. Remission in Rheumatoid Arthritis: Wishful Thinking or Clinical Reality? Semin Arthritis Rheum 2005;185-196.
PubMed
7) Prevoo ML, van Gestel AM, van T Hof MA et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35: 1101-1105.
 
8) Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004: 43: 1252-1255.
PubMed
9) Mierau M, Schoels M, Gonda G et al. Assessing remission in clinical practice. Rheumatology 2007;46: 975-979.
PubMed
10) Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): asingle-blind randomised controlled trial. Lancet 2004;364: 263-9. 11) van Tuyl LH, Lems WF, Voskuyl AE et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90％remission in a pilot trial. Ann Rheum Dis 2008;67: 1574-1577.
 
12) Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823-7.
PubMed
13) Cohen G, Gossec L, Dougados M et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007;66: 358-63.
PubMed
14) Tanaka Y, Takeuchi T, Mimori T. Discontiuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010: 69: 1286-1291
 
15) Aletaha D, Funovits J, Breedveld FC et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009;60: 1242-1249.
PubMed
16) Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-67.
PubMed
17) Saleem B, Brown AK, Keen H et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: Aclinical and imaging comparative study. Arthritis Rheum 2009;60: 1915-22.
 
18) Quinn MA, Conaghan PG, O: Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized double-blind, placebo-controlled trial. Arthritis Rheum 2005;52: 27-35.
PubMed
19) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: arandomized trial. Ann Intern Med 2007: 146: 406-415.
 
20) van der Kooij SM, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. Drug-free remissiOn, functioning and radiographic damage after 4 years of response-driven treatment in patients with recentonset rheumatoid arthritis. Ann Rheum Dis 2009;68: 914-921.
PubMed
21) 塩沢俊一, 全身性エリテマトーデスSLEの発症病因の解明, 臨床検査学教育 2010;2: 118-127.
 
22) Tsumiyama K, Miyazaki Y, Shiozawa S, Self-organized criticality theory of autoimmunity. PLOS ONE 2009;4 (12): e8382.
PubMed
23) Shiozawa S, Tsumiyama K. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009; 8: 1539-1543.
 
P.17 掲載の参考文献
1) Strehler BL. Time, Cell, and aging. New York, Acadernic Press, 1977.
 
2) Francheschi C, Valensin S, Fagnoni F, et al. Biomarkers of immunosenescence within an evolutionary perspective: the challenge of the role of antigenic load Exp Gerontol 1999;34: 911-921.
 
3) Goto M. Inflammaging (inflammation+aging): A driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? BioScience Trends 2008;2: 218-230.
 
4) Williams CG. Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957;11: 398-411.
 
5) Licastro F, Candore G, Lio D, et al. Innate immunity in aging: a key for understanding age-related disease. Immun Aging 2005;18: 2-8.
 
6) Utsinger PD, Zvaifler NJ, Ehrlich GE. Rheumatoid arthritis, 1985, Philadelphia, Lippincott.
 
7) Goto M, Miller RW. From premature gray hair to helicase-Werner syndrome: Implications for aging and cancer, 2001, New York, Karger.
 
8) Osborne TB, MendelLB, Ferry EL. The effect of retardation of growth upon the bree (ling periOd and duration of life in rats. Science l 917;45: 294-295.
 
9) Bauer JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444: 21-26.
 
10) Haigis MC, Guarante LP. Mammalian sirtuins-emerging roles in physiology, aging and calorie restriction. Genes Dev 2006;20: 2913-2921.
 
P.22 掲載の参考文献
1) 森 幹士, 池川志郎, 茶野徳宏, ら. 強直性脊椎炎の遺伝的要因(総説). 整形外科 2002;53: 1249-1253.
 
2) Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973: 1: 904-907.
PubMed
3) Schlosstein L, Terasaki PI, Bluestone R, et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288: 704-706.
 
4) Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol 2010;22: 126-132.
PubMed
5) Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev 2010;233: 162-180.
PubMed
6) Olivieri I, D'Angelo S, Scarano E, Santospirito V, Padula A. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis. Arthritis Rheum 2007;56: 2805-2807.
 
7) Cauli A, Vacca A, Mameli A, et al. A Sardinian patient with ankylosing spondylitis and HLA-B＊2709 coっccurring with HLA-B＊1403. Arthritis Rheum 2007;56: 2807-2809.
 
8) Nejentsev S, Howson JM, Walker NM, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450: 887-892.
 
9) Jarvinen P. Occurrence of ankylosing spondylitis in a nationwide series of twins. Arthritis Rheum 1995;38: 381-383.
 
10) Rubin LA, Amos CI, Wade JA, et al. Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994: 37: 1212-1220.
PubMed
11) Wellcome Trust Case Control Consortium;Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies auto immunity variants. Nat Genet 2007;39: 1329-1337.
 
12) Rueda B, Orozco G, Raya E, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008: 67: 1451-1454.
PubMed
13) Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008;58: 1020-1025.
PubMed
14) Karaderi T, Harvey D, Farrar C, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirrned by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford) 2009;48: 386-289.
PubMed
15) Pimentel-Santos FM, Ligeiro D, Matos M, et al. Association of IL23R and ERAP l genes with ankylosing spondylitis in a Portuguese population. Clin Exp Rheumatol 2009;27: 800-806.
 
16) Davidson SI, Wu X, Liu Y, et al. Association of ERAP 1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum 2009;60: 3263-3268.
 
17) Sung IH, Kim TH, Bang SY, et al. IL-23R polymorphisms in patients with ankylosing spondylitis in Korea. J Rheumatol 2009;36: 1003-1005.
 
18) Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel (lisease gene. Science 2006: 314: 1461-1463.
 
19) Dubinsky MC, Wang D, Picornell Y, et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis 2007;13: 511-515.
PubMed
20) Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL 12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80: 273-290.
 
21) Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR 1-binding protein that promotes TNFR l ectodomain shedding. J Clin Invest 2002;110: 515-526.
 
22) Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multi-functional aminopeptidase, aminopeptidase regulator of TNF receptor type l shedding. J Immunol 2003: 171 : 6814-689.
 
23) Cui X, Rouhani FN, Hawari F, Levine SJ. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem 2003;278: 28677-28685.
PubMed
24) Kanaseki T, Blanchard N, Hammer GE, Gonzalez F, Shastri N. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006;25: 795-806.
PubMed
25) Furuichi T, Maeda K, Chou CT, et al. Association of the MSX2 gene polymorphisms with ankylosing spondylitis in Japanese. J Hum Genet 2008;53: 419-424.
PubMed
26) Sieper J. Can structural damage be prevented in ankylosing spondylitis? Curr Opin Rheumato12009; 21 : 335-339,
PubMed
27) 森 幹士. 抗TNF-α療法による滑膜炎症と骨・軟骨破壊との乖離 リウマチ病セミナーXIX (七川歡次監修). 2008, p136-142, 大阪, 永井書店.
 
28) 森 幹士, 井上康二. TNF阻害薬は強直性脊椎炎の進行を抑制するか? リウマチ科 2008;40: 535-538.
 
29) Ward MM, Hendrey MR, Malley JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 2009;61: 859-866.
PubMed
30) Maksymowych WP, Landew6 R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56: 1846-1853.
PubMed
31) Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123: 1037-1044.
PubMed
32) Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356: 580-592.
PubMed
33) Mannon PJ , Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351: 2069-2079.
PubMed
P.29 掲載の参考文献
1) Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed. 1996: 63: 163-170.
PubMed
2) Harden LM, du Plessis 1, PoOle S, et al. Interleukin (IL)-6 and IL-l beta act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav Immun 2008;22: 838-849.
 
3) Nishikawa T, Hagihara K, Serada S, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 α is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008; 180: 3492-3501.
 
4) Hagihara K, Nishikawa T, Sugamata Y, et al. Essential role of STAT3 in cytokine-driven NF-kB-mediated serum amyloid A gene expressiOn. Gerle to Cell 2005;10: 105HO63.
 
5) Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009;46: 387-393.
 
6) Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003: 15: 581-586.
PubMed
7) Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: arandomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371: 998-1006.
 
8) Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemiconset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005;28: 231-238.
PubMed
P.33 掲載の参考文献
1) Sato T, Ishikawa O, Ihn H, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology 2009;48: 1570-1574.
 
2) Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U 11/U 12 RNP antibodies in systemic sclerosis: anew serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009;61: 958-965.
 
3) Aggarwal R, Lucas M, Fertig N, et al. Anti-U3RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009;60: 1112-1118.
 
4) Dieude P, Guedj M, Avouac J, et al. Association between the IRF5 re2004640 functional polymorphism and systemic sclerOsis: anew prospective for pulmonary fibrosis. Arthritis Rheum 2009: 60: 225-233.
 
5) Rullo OJ, Woo JM, Hoftman Ad, et al. Association of IRF5 polymorphisms with activation of the Interferon一αpathway. Ann Rheum Dis 2009;69: 611-617.
 
6) Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18: 2071-2077.
PubMed
7) Dieuda P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009;60: 2472-2479.
PubMed
8) ten Freyhaus H, Dumitrescu D, Bovenschulte H, et al. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009;98: 265-267.
PubMed
9) Akhmetshima A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60: 219-224.
PubMed
10) Chung L, Florentino DF, Benbarak MJ, et al. Molecular framework for respOnse to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009;60;584-591.
 
11) Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60;578-583.
PubMed
12) Daoussis D, Liossis SN, Tsamanda AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010: 49: 271-280.
 
13) Denton CP, Engelhart M, Tvede N, et al, An open-1abel pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009;68: 1433-1439.
PubMed
14) Fuschiotti P, Medsger TA Jr, Morel PA. Effector CD8+Tcells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009: 60: 1119-1128.
 
15) Higashi-Kuwata N, Makino T, Inoue Y, et al. Alternatively activated macrophages (M2 macrophages) in the skin of patients with localized scleroderma. Exp Dermatol 2009;18: 727-729
 
P.46 掲載の参考文献
1) Cowper SE. Nephrogenic Systemic Fibrosis: An Overview. J Am CollRadiol 2008;5: 23-28.
PubMed
2) Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-1ike cutaneous diseases in renal-dialysis patients. Lancet 2000: 356: 1000-1001.
 
3) Moschella SL, Kay J, Mackool BT, et al. Case records of the Massachusetts General Hospital. Week ly clmicopathologicalexercises. N Engl J Med 2004;351: 2219-2222.
 
4) Mendoza FA, Artlett CM Sandorfi N, et al. Description of 12 cases of nephrogenicfibrosingdermopathy and review of the literature. Semin Arthritis Rheum 2006;35: 238-249.
PubMed
5) Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188: 586-592.
PubMed
6) Schieren G, Wirtz N, Altmeyer P, et al. Nephrogenic systemic fibrosisea-progressive disablimgdisease with limited therapeutic options. J Am Acad Dermatol 2009: 61: 868-874.
PubMed
7) Ting WW, Stone MS, Madison KC, et al. Nephrogenicfibrosing dermopathy with systemic involvement. Arch Dermatol 2003: 139: 903-906.
PubMed
8) Cowper SE, Bucala R, Leboit PE. Nephrogenicfibrosingdermopathy/nephrogenic systemic fibrosis-setting the record straight. Semin Arthritis Rheum 2006;35: 208-210.
PubMed
9) Grobner T. Gadoliniumda specific trigger for the development of nephrogenicfibrosingdermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21: 1104e8.
PubMed
10) Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am SocNephrol 2006;17: 2359e62.
PubMed
11) Joffe P, Thomsen HS, Meusel M Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. AcadRadio11998;5: 491-502.
 
12) 対馬義人. Nephrogenic systemic fibrosis (NSF:腎性全身性線維症)-MRI用造影剤ガドリニウム製剤による新しい副作用- CLINICIAN 2007 NO.562 112-121.
 
13) Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008: 180: 830-835.
PubMed
14) Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010: 83: 590-595.
PubMed
15) Chrysochou C, Buckley DL, Dark P. Gadolinium-Enhanced Magnetic Resonance Imaging for Renovascular Disease and Nephrogenic Systemic Fibrosis: Critical Review of the Literatureand UK Experience JOURNAL OF MAGNETIC RESONANCE IMAGING 2009;29: 887-894.
 
16) Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemicfibrosis: risk factors and incidence estimation. Radiology 2007;243: 148-157.
PubMed
17) 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン」 (第2版: 2009/9/2) 日本医学放射線学会・日本腎臓学会) 日本腎臓学会ホームページ内: http://www.jsn.or.jp/jsn_new/news/guideline_nsf_090902.pdf
 
18) 渋井香織, 片岡浩史, 佐藤尚代. CKD stage 3: eGFR>30ml/min/1.73m2の腎機能がありながら繰り返す造影MRIにより腎性全身性線維症をきたした一例. 日腎会誌 2009;51
 
P.55 掲載の参考文献
1) McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR I, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97: 133-144.
 
2) 塩沢俊一: インフラマゾームと自己炎症症候群. 七川歡次監修, 監修. リウマチ病セミナーXX. 2009, p114-123. 大阪, 永井書店.
 
3) Kastner D, Brydges S, Hull K. Periodic Fever Syndromes. New York, USA: Oxford University Press; 2007.
 
4) Masters SL, Simon A, Aksentijevich 1, et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (＊) . Annu Rev Immunol 2009;27: 621-668.
 
5) Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40: 1879-1885.
PubMed
6) Tsuchiya-Suzuki A, Yazaki M, Nakamura A, et al. Clinical and genetic features of familial Mediterra-nean fever in JaparL J Rheumato12009;36: 1671-1676.
 
7) Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008;29: 803-808.
PubMed
8) 井田弘明, 江口勝美. TRAPSの診断と新しい治療法の展開. 日本臨床免疫学会誌 2007;30: 90-100.
 
9) Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR l mutants in TNFR1-associated periodic fever syndrome (TRAPS) Blood 2006;108: 1320-1327.
 
10) Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an auto inflammatory disorder. Medicine (Baltimore) 2002;81: 349-368.
 
11) Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-lbeta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004: 20: 319-325.
 
12) Franchi L, Eigenbrod T, Munoz-Planillo R, et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10: 241-247.
PubMed
13) Saito M, Nishikomori R, Kambe N, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 2008;111: 2132-2141.
PubMed
14) Fujisawa A, Kambe N, Saito M, et al. Disease-associated mutations in CIAS l induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood 2007;109: 2903-2911.
 
15) 金澤伸雄. 【Autoinflammatory syndromeの新たなる展開と治療法の確立】Blau症候群と若年発症サルコイドーシスの臨床像とCARD15/NOD2遺伝子異常. 日本臨床免疫学会会誌 2007;30: 123-132.
 
16) Miceli-Richard C, Lesage S, Rybojad M, et al. CARD1 5 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20.
 
17) Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD 15mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005; 105: 1195-1197.
 
18) Rose CD, Wouters CH, Meiorin S, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006;54: 3337-3344.
PubMed
19) Okafuji I, Nishikomori R, Kanazawa N, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009;60: 242-250.
PubMed
20) Brydges S, Athreya B, Kastner D. periodic fever syndrome in children. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, eds. Textbook of Pediatric Rheumatology (ed 5th) . Philadelphia: Elsevier Saunders;2005: 657-670.
 
P.65 掲載の参考文献
1) http://www.music-tel.com/naosuke/nab-h/200209192sake.html
 
2) 白倉克之, 澤山 透. アルコール関連疾患をめぐって, アルコール医療入門, 2003, p1-5, 東京, 新興医学出版社.
 
3) 角田 透, 照屋浩司, 武田伸郎. アルコール飲料の消費とアルコール関連疾患の現況について. アルコール医療入門, 2003, p6-11, 東京, 新興医学出版社.
 
4) Bradlow A, Mowat AG. Alcohol consumption in arthritic patients: clinical Znd laboratory studies. Ann Rheum Dis 1985;44: 163-168.
 
5) Edwards G, Chandler J, Hensman C, et al. Drinking ina Lomdon Suburb. (1) Correlates of normal drinking. Q J Stud Alcohol 1972;suppl 6: 69-93.
 
6) Hazes JMW, Dijkmans BAC, Vandenbroucke, et al. Lifestyle and the risk of rheumatoid arthritis-cigarette Smoking and alcohol consumption. Ann Rheum Dis 1990: 49: 980-982.
 
7) Voigt LF, Koepsell TD, Nelson JL, et al. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994: 5: 525-532.
PubMed
8) Cerhan JR, Saag KG, Crisswell LA, et al. Blood transfusion alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol 2002: 29: 246-254.
 
9) Pederson M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without autoantibodies against cyclic citrullinated peptides. Arthr Res Ther 2006; 8: 1186-2022.
 
10) Pedersen M, Jacobsen S, garred P, et al. Strong combines gene-emvironment effects in ant-cyclid citrullinated peptide-psitive rheumatoid arthritis. Arthrits Rheum 2007;56: 1446-1453.
 
11) Kallberg H, Jacobsen S, Bengtsson C, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-contoro l studies. Ann Rheum Dis 2009; 68: 222-227.
 
12) Kim SK, Park SH, Shin IM, et al. Anti-cyclic cirullinated peptide antibidy, smoking, alcohol consumption, and desease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J Rheumato12008;35: 995-1001.
 
13) Bourikas LA, Kriitikos HD, Papakostantinou OG, et al. Chronic alcohol consumption as a predisposing. factor for multiple tendon ruptures in unusual sites in a patient with rheumatoid arthritis. Clin Exp Rheumatol 2007;25: 461-463.
 
14) 関節リウマチ患者のための自己管理マニュアル. 平成17年度厚生労働科学研究.
 
15) Rajakulendran S, Gadssby K, ＆ Deighton C. Rheumatoid arthritis, alcohol, lefluomide and methotrexate, can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified？Musculoskelet, Care 2008;6: 233-246.
 
16) Chakravarty K, McDonald H: ullear T, et al. on behalf of the British Society for the Rheumatology, British Health proffessionals in Rheumatology. Standards, Guidelines and Adult Working Groupe in consultation with the British Association of Dermatologists (2008) . Available at http//rheumatology. Oxford journals, org/cgi/content/full/ke 1216/DCI
 
17) 国民衛生の動向. 2009;56: 99. 厚生統計協会, 東京.
 
18) Nagata C, Fujita S, Hirotosi I, et al. Systemic lupus erythematosus: acase control epidemiologic study in Japan. Int J Dermatol 1995: 34: 333-337.
 
19) Hardy CH, Palmer BP, Muir KR, et al. Smoking history, alcohol consumption, and systemic lupus erythematosus Ann Rheumn Dis: 1998: 57: 451-455.
 
20) Ghaussy NO, Sibbitt WL, ＆ Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematos, J Rheumatol 2001;28: 2449-2453.
 
21) Benggtsson AA, Rylander L, Hagmar L, et al. Risk factors for developing systemic lupus erythematosus: acase-control study in southern Sweden. Rheumatology 2002: 41: 563-571.
 
22) Washio M, Horiuchi T, Kiyohara C, et al. Smoking, drinking, sleeping, habits, and other lifestyle factors and the risk of systemic lupus erythematosus in Japanese females: findings from the KYSS study. Mod Rheumato12006;16: 151-157.
 
23) 丸山勝也, 横山 顕. アルコールと代謝疾患-糖尿病, 痛風. アルコール医療入門. 2001, p41-44, 東京, 新興医学出版社.
 
24) Zhang Y, Woods R, Chaisson CE, et al: Alcohol consumption as a trigger of recurrent, gout attacks. Amer J Med 2006: 119: 13-18.
 
25) Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident, gout in men. Lancet 2004;363: 1277-1281.
PubMed
26) 日本痛風・核酸代謝学会: 高尿酸血症・痛風の治療ガイドライン ダイジェスト版:電通サドラー・アンド・ヘネシー株式会社, 東京, 2002.
 
27) Myllykangas-Luosujarvi R, Aho K, Lehtinen K, et al. Increased incidence of alcohol-related deaths from accidents and violence in subjects with ankylosing spondylitis. Brit J Rheumatol 1998;37: 688-690.
 
28) Calin A. Survival, alcohol and deaths in ankylosing spondylitis, Brit J Rheumatol 1998;37: 600-601.
 
29) James Wh. The rates of alcohol-related deaths from accidents and violence in subjects with ankylosing spondylitis and rheumatoid arthritis, Brit J Rheumato1. 1998;37: 91.
 
30) James WH. Sex ratios and hormones in HLA-related rheumatic diseases. Ann Rheum Dis 1991;30: 401-404.
 
31) Daitzman R, Zuchermaqn M. Disinhibitory sensation-seaking and gonadal hormones. Personal Indiv Diff 1980;1: 103-110.
 
32) Kemper TD. Social stracture and teststerone. London;Rutgers University: ress. 1990.
 
33) Boe DM, Nelson B, Zhang P, et al. Alcoho1-induces supptession of lung chemokine production and the host defense response to streptococcus pneumoniae. Alcohol Clin Exp Res 2003;27: 1838-1845.
 
34) Encke J ＆ Wands JR. Ethanol inhibition: The humoral and cellular immune response to hepatitis C virus NS8 protein after genetic immunization. Alcohol Clin Exp Res 2000;7: 1063-1069.
 
35) Mandrekar P, Catalano D, White B, et al. Moderate alcohol intake in humans attenuates monocyte inflammatory responses: Inhibition of nuclear regulatory factor Kappa B and induction of Interleukin (0.Alcohol Clin Exp Res 2006;30: 136-139.
 
36) Cooper C, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Alcohol pertuurbs HCV RNA after KAART 2005: 41: 5107-5109.
 
37) Jonsson IM, Verdrengh M, Brisslert M, et al. Ethanol prevents development of destructive arthritis. PNAS: 2007: 104: 258・263.
 
P.78 掲載の参考文献
1) 前田恵治. 結合組織病における肺高血圧症. 七川歓次監修, リウマチ病セミナーXVI. 大阪: 永井書店; 2005: 1-9.
 
2) Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension (Proceeding of the 4th world symposium on pulmonary hypertension) . JAm Coll Cardiol 2009; 54Suppl S;43-59.
 
3) Barst RJ, Gibbs SR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension (Proceeding of the 4th world symposium on pulmonary hypertension) . J Am Coll Cardio12009;54 SupPl S;78-84.
 
4) 厚生労働省統計資料 平成20年度特定疾患医療受給者証交付件数 http://www.nanbyou.or.jp/what/nan_kouhul_win.htm#pO1
 
5) 東條 毅, ら. 膠原病四疾患における肺高血圧症の頻度に関する疫学調査 厚生省特定疾患 皮膚・結合組織疾患調査研究班, 混合性結合組織病分科会, 平成10年度研究報告書;1999: 3.
 
6) 半田俊之介. 肺高血圧症 成因, 診断, 治療に関する最新研究動向 肺高血圧症を呈する主要疾患とその病態 先天性及び後天性心疾患に合併する肺高血圧症. 日本臨牀 2001;59: 1175-1180.
 
7) 勝田悌実. 肺高血圧症 成因, 診断, 治療に関する最新研究動向 肺高血圧症を呈する主要疾患とその病態 門脈肺高血圧. 日本臨牀 2001;59: 1186-1192.
 
8) Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351: 1425-1436.
PubMed
9) Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenaphil. J Biol Chem 1999: 274: 13729-13732.
 
10) Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertensiorL NEngl J Med 2005;353: 2148-2157
 
11) Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary hypertension associated with connective tissue diseases. 2007: 34: 2417-2422
 
12) 国枝武義. MCTDの病態別治療指針 肺高血圧症 鳥飼勝隆, 柏木平八郎, 東条毅編 厚生省特定疾患混合性結合組織病調査研究班混合性結合組織病の治療指針1996: 26-31
 
13) 吉田俊治. 膠原病性肺高血圧症. 臨床リウマチ 2008;20: 95-100.
 
14) 吉田俊治, 岡田 純, 近藤啓文, ら. MCTD合併肺高血圧症の治療指針(案). 厚生省特定疾患対策研究事業混合性結合組織病に関する研究班平成13年度研究報告書: 2000; 18-21.
 
15) Tanaka E, Harigai M, Tanaka M, et al. Pulmomary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment J Rheumatol 2002;29: 282-287
 
16) Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006: 130: 182-189,
PubMed
17) Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2008;58: 521-531.
PubMed
18) Con (lliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009: 179: 151-157.
 
19) Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35: 989-93
 
20) 木村英夫, 宮地克雄, 松原広己. 新たな治療薬としてのイマチニブ. 総合臨牀 2009;58:2234-2237.
 
21) 伊達洋至. 肺高血圧症に対する肺移植・心肺移植. 総合臨牀 2009;58:2338-2342.
 
P.82 掲載の参考文献
1) 長本行隆, 岩崎幹季, 坂浦博伸, ら. 圧迫性頸髄症に脊髄サルコイドーシスを合併した1例. 中部整災誌 2009;52: 1095-1096.
 
2) 安藤哲朗, 亀山 隆, 鈴木和広, ら. 脊髄サルコイドーシス-診療上の問題点と患者への情報提供-. 脊椎脊髄 2006;19: 694-701.
 
3) 山本正彦. サルコイドーシスの病態・疫学・診断. 神経内科 1996;45: 187-196.
 
4) 亀山 隆, 安藤哲朗. 脊髄サルコイドーシス. 脊椎脊髄 2007;20: 1063-1068.
 
5) Junger SS, Stern BJ,Levine SR, et al. Intramedullary spinal sarcoidosis: Clinical and magnetic resonance imaging characteristics. Neurology 1993;43: 333-337.
PubMed
6) Baruah JK, Glasauer FE, Sil R, et al. Sarcoidosis of the cervical spinal cannal: Case report. Neurosurgery 1978;33: 216-218.
 
7) Nagai H, Ohtsubo K, Shimada H, et al. Sarcoidosis of the spinal cord. Report of an autopsy case and review of the literature. Acta Pathol Jpn 1985: 35: 1007-1022.
PubMed
8) 世沢 薫, 森田正次, 宮本 敬, ら. 皮膚サルコイドーシスを合併した髄内浮腫を伴う頸髄症の1例. 臨整外 2004;39: 865-869.
 
9) Oe K, Doita M, Miyamoto H, et al. Is extensive cervical laminoplasty an effective treatment for spinal cord sarcoidosis combined with cervical spondylosis? Eur Spine J 2009;18: 570-576.
PubMed
10) 酒井義人, 松山幸弘, 中村博司, ら. 頸髄症を合併した脊髄サルコイドーシス-除圧術は予後を変えるか?-. 日本脊椎脊髄病学会雑誌 2007;18: 54.
 

骨関節,脊椎,神経

P.96 掲載の参考文献
1) Yamori Y Development of the spontaneously hypertensive rat (SHR) and of various spontaneous rat models, and their implications. In: Wde Jong editor. Handbook of Hypertension, Experimental and Genetic Models of Hypertension vol 4, Amsterdam: Elsevier Science Publishers BV;1984: 224-239.
 
2) Hirano T, Iwasaki K, Sagara K, et al. Necrosis of the femoral head in growing rats. Occlusion of lateral epiphyseal vessels. Acta Orthop Scand l 989;60: 407-410.
 
3) Iwasaki K, Hirano T, Sagara K, et al. Idiopathic necrosis of the femoral epiphyseal nucleus in rats. Clin Orthop Relat Res 1992;277: 31-40.
PubMed
4) Fasshauer MJ, Klein S, Neumann M, et al. Hormonal regulation of adiponectin gene expression in 3T3-LI adipocytes. Biochem Biophys Res Commun 2002;290: 1084-1089.
 
5) Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89: 2548-256.
 
6) Naito S, Ito M, Sekine I, et al. Femoral head necrosis and osteopenia in stroke-prone spontaneously hypertensive rats (SHRSPs) . Bone 1993;14: 745-753.
PubMed
7) Arlet J, editor. A traumatic necrosis of the femoral head: general report. In: Schoutens AAJ, Gardeniers JWM, Hughes SPF edditors. Bone circulation and vascularization in normal and pathological conditions, New York: Plenum;1993: 235.
 
8) Murata M, Kumagai K, Miyata N, et al. Osteonecrosis in stroke-prone spontaneously hypertensive rats: Effect of glucocorticoid J Orthop Sci 2007: 12: 289-295.
PubMed
9) Suzuki M, Kumagai K, Osaki M, et al. Osteonecrosisof femoral head in the stroke-prone spontaneously hypertensive rats, especially old rats. Clin Exp Hypertens 2008;30: 689-697.
PubMed
10) Halleux CM, Declerck PJ, Tran SL, et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999;84: 4097-4105.
PubMed
11) Yamamoto Y, Ishizu A, Ikeda H, et al. Dexamethasone increased plasminogen activator inhibitor-1 expression on human umbilical vein endothelial cells: an additive effect to tumor necrosis factor-alpha. Pathobiology 2004: 71: 295-301.96
 
13) Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res 2001;386: 173-178.
PubMed
14) Quanjun Cui, Gwo-Jaw Wang, Chin-Chien su, et al. Lovastatin Prevents Steroid Induced Adipogenesis and Osteonecrosis. Clinical orthopaedics and Related research 1997: 344: 8-19.
 
15) Michael AM, Lynne CJ, David SH. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006: 88: 1117-1132.
 
16) Hirota Y. Etiology of idiopathic osteonecrosis of the femoral head: nationwide epidemiologic studies in Japan. Osteonecrosis: Etiology, Diagnosis, and Treatment 1997: 51-58.
 
17) Atsumi T, Muraki M, Yoshihara S, et al. Posterior rotational osteotomy for the treatment of femoral head osteonecrosis. Arch Orthop Trauma Surg l 999;119: 388-393.
 
18) Sugioka Y. Transtrochanteric anterior rotational osteotomy of the femoral head in the treatment of osteonecrosis affecting the hip: a new osteotomy operation. Clin Orthop Relat Res 1978;130: 191-201.
PubMed
19) Cheras PA. Role of hyperlipidemi, hypercoagulability, and hypofibrinolysis in osteonecrosis and osteoarthritis. In: Urbaniak JR, Jones JPJr, editors. Osteonecrosis: etiology, diagnosis, and treatment. Rosemont, IL.: American Academy of Orthopedic Surgeons;1997: 97-104.
 
20) Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatrnent. Semin Arthritis Rheum 1999;28: 211-267.
 
P.107 掲載の参考文献
1) Saupe E Beitrag zur patella bipartita Fortschr Rontgenstr l 921: 28: 37-41.
 
2) Jones R. Fracture of the base of the fifth metatarsal bone by indirect violence. Ann Surg 1902;35: 697-700.
PubMed
P.118 掲載の参考文献
1) 西林保朗, 小形晶子. 筋筋膜痛症候群. リウマチ病セミナーXVII (七川歡次監修), 2006, p101-113, 大阪, 永井書店.
 
2) Sheon RP, Moskowitz RW, Goldberg VM Soft tissue rheumatic pain: recognition, management, and prevention, 3rd ed, 1996, Baltimore, Williams＆Wilkins.
 
3) Travell JG, Simons DG. Myofascial pain and dysfunction. The trigger point manual. (volume 1) The upper extremities. 1983, Baltimore, Williams＆Wilkens.
 
4) 特集: 機能性身体症候群. 日本臨牀 2009;67: 1644-1809.
 
5) 志水正敏. リウマチ患者に多い訴えとその対策. リウマチ病セミナーXIX (七川歡次監修), 2008, p151-158, 大阪, 永井書店.
 
6) Wallace DJ, Clauw DJ. Fibromyalgia＆other central pain syndromes. 2006, Lippincott Williams＆ Wilkins.
 
7) 私信: 本山豪霊
 
8) 若杉文吉, 持田奈緒美. 星状神経節ブロック療法-安全な手技確立と正しい理解のために-2007, 東京, 真興交易医書出版部.
 
9) 七川歡次. リウマチ医療の変遷. 最新整形外科学体系19. 関節疾患と類縁疾患 (越智隆弘総編集), 2007, p2-9, 東京, 中山書店.
 
10) 行岡正雄. 自律神経とRA. リウマチ病セミナーXIX (七川歡次監修), 2008, p10-18, 大阪, 永井書店.
 
11) 西林保朗. 線維筋痛症のレゾンデートル-運動器疾患患者の全人的ケアへのいざない- リウマチ病セミナーXIX (七川歡次監修), 2008, p58-67, 大阪, 永井書店.
 
12) 花岡一雄, 有田英子, 井手康雄, ら. 侵害受容性慢性疾痛疾患. 慢性疾痛の理解と病診連携 (宮崎東洋, 北出利勝編集), 2008, 東京, 新興交易医書出版部.
 
13) 後藤文雄, 天野隆弘. 臨床のための神経機能解剖学. 1992, 東京, 中外医学社.
 
14) 國本雅也. 脊椎・脊髄疾患. 最新自律神経学 (宇尾野公義, 入來正躬監修), 2007, p256-262, 東京, 新興医学出版社.
 
15) 永田勝太郎. 全人的医療からみたFSS. 日本臨牀 2009;67: 1701-1708.
Medical*Online
16) 神原憲治, 福永幹彦. FSSの病態. 日本臨牀 2009;67: 1669-1675.
Medical*Online
17) 中尾睦宏. FSSの疫学. 日本臨牀 2009;67: 1661-1668.
Medical*Online
18) 野口光一. 痛みの神経生物学. 第12回近畿リウマチ病研究会講演集 (七川歡次, 志水正敏監修), 2001, p47-54, 近畿リウマチ病研究会.
 
19) 変形性膝関節症の痛みは何処のもの? 第12回近畿リウマチ病研究会講演集 (七川歡次, 志水正敏監修), 2001, p39-45, 近畿リウマチ病研究会.
 

燐・カルシウム代謝

P.126 掲載の参考文献
1) Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004;291: 1999-2006.
 
2) Matsumoto T, Miki T, Hagino H, et aL A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation;a randomized double-blind, placebo-controlled clinical trial. J Clin endocrinol Metab 2005;90: 5031-6.
PubMed
3) Matsumoto T, Kubodera N. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25 (OH) D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 2007;103: 584-6.
 
4) Bouxsein ML, Glen P, Glass EV, et al. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. J Bone Joint Surg Am 2009;91: 1329-1338
 
5) Uusi-Rasi K, Beck TJ, Semanick LM, et al. Structual ehhects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 2006: 17: 575-586 Epub
 
6) Cano A, Dapia S, Noguera I, et al. Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice. Osteoporos Int 2008; 19: 793-800
 
7) Grady D, Cauley JA, Stock JL, et al. Effect of Raloxifene on all-cause mortality. Am J Med. 2010;123: 469. e1-7.
 
8) Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23: 1923-1934.
PubMed
9) Choi A, Gang H, Chun I, et al. The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int. J. Pharm. 2008;357: 126-131.
PubMed
10) Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphos-phonates. J Pharmacol Exp Ther 2001;296: 235-242.
 
11) Morii H, et al. A randomized controlled trial with ONO-5920 (Minodronate/YM529) in Japanese patients with postmenopausal osteoporosis. J Bone Miner Res 2002;17 (Suppl 1): M342.
 
12) Hagino H, Nishizawa Y, Sone T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 2009;44: 1078-1084E pub.
 
13) Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis. Osteoporos Int 2009;20: 1429-1437 Epub.
 
14) Chesnut CH 3rd Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19: 1241-9.
 
15) Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356: 1809-1822.
PubMed
16) Lyles KW, Col 溶-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357: 1799-1809.
 
17) Bekker PJ, Holloway DL, Rasmussen AS, et al: Asingle-dose placebO-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066.
 
18) McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Eng J Med 2006;354: 821-831.
 
19) Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmeno-pausal women with osteoporosis. N Eng J Med 2009;361: 756-765.
 
20) Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long term continueed, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43: 222-9.
 
21) Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998;95: 13453-8.
PubMed
22) Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996;271: 12511-6.
 
23) Asagiri M, Hirai T, Kunigami T, et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008;319: 624-7.
PubMed
24) 杉本利嗣. Calcium-sensing receptor. リウマチ病セミナーX (七川歡次監修). 1999, p242-251, 大阪, 永井書店.
 
25) Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459-468.
PubMed
26) Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporosis Int 2009;20: 1663-73.
PubMed
27) Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis : Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005: 90: 2816-2822.
PubMed
28) Reginster JY, Felsenberg D, Boonen S, et al. Effects of longミterm strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis;results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008: 58: 1687-1695.
 
29) Seeman E, Vellas B, Benharmou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21: 1113-1120.
 
30) Engleman VW, Nickols GA, Ross FP, et al. A peptidomimetic antagonist of the α v β 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. The Journal of Clinical Investigation 1997; 99: 2284-2292.
 
31) Zou W, Kitaura H, Reeve J, et al. Syk c-Src, the α v β 3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007;176: 877-888.
 
32) McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intren Med 2005;165: 1762-8.
 
33) Henriksen K, Neutzsky-Wulff AV, Bonewald LF, et al. Local communication on and within bone cotrols bone remodeling. Bone 2009;44: 1026-1033.
PubMed
34) Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344: 1434-1441.
PubMed
35) Black DM, Bilezikian JP, Ensrud KE et al: One year of alendronate after one year Of parathyroid hormone (1-84) for osteoiporosis. N Engl J Med 2005;353: 555-565.
PubMed
36) Black DM, Greenspan SL, Ensrud KE, et al: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349: 1207-1215.
 
37) Wan W, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes dev 2008;22: 2968-2979.
 
38) Vahle JL, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30: 312-321.
PubMed
39) Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407: 530-5.
PubMed
40) Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107: 513-523.
PubMed
41) Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70: 11-9.
PubMed
42) Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J2005;19: 1842-4.
 
43) Van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199: 805-814.
 
44) Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-588.
 
45) Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111: 305-317.
PubMed
46) Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005: 434: 514-520.
PubMed
47) Sato S, Hanada R, kimura A, et al. Central control of bone remodeling by neuromedin U. Nat Med 2007; 13: 1234-1240.
PubMed
48) Yadav VK, Ryu JH, Suda NC et al. Lrp5 controls bone formation by inhibiting serotorlin synthesis in the duodenum. Cell 2008;135: 825-837.
 
49) Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is apotential bone anabolic treatment for osteoporosis. Nat Med 2010;16: 308-312 Epub.
 
P.135 掲載の参考文献
1) Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-1117.
PubMed
2) Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 2007: 65: 415-423.
PubMed
3) Advisory Task Force on Bisphosphonate-related osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosph onate-related osteonecrosis of the jaws. J Oral Mexillofac Surg 2007;65: 369-376.
 
4) 高橋喜久雄, 川畑彰子, 小池博文, ら. ビスフォスフォネートによって発症したと考えられた上顎骨壊死の1例. 日口外誌 2006;52: 416-419.
 
5) 岸 直子, 足立忠文, 小泉英彦, ら. ビスフォスフォネートにより発症した下顎骨壊死の1例. 日口外誌 2007;53: 28-32.
 
6) Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006: 35: 155-160.
PubMed
7) 米田俊之. ビスフォスフォネート製剤関連顎骨壊死の病態とそのマネージメント. 日口外誌 2010;56: 286-291.
 
8) Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63: 1567-1575.
PubMed
9) 島原政司, 有吉靖則, 今井 裕, ら. ビスフォスフォネート投与と関連性があると考えられた顎骨骨髄炎ならびに顎骨壊死に関する調査. 日口外誌 2007;53: 594-602.
 
10) 浦出雅裕, 田中徳昭, 嶋田 淳, ら. ビスフォスフォネート投与と関連性があると考えられた顎骨骨髄炎ならびに顎骨壊死30症例に関する追跡調査～2年後の現状について～. 日口外誌 2009;55: 553-561.
 
11) 浦出雅裕. ビスフォスフォネート治療による顎骨壊死発症の現状. 日口外誌 2010;56: 292-297.
 
12) Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28: 365-383.
PubMed
13) Bell BM, Bell RE. Oral bisphosphonates and dental implants: aretrospective study. J Oral Maxillofac Surg 2008;66: 1022-1024.
 
14) Grant BT, Amenedo C, Freeman K, et al. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66: 223-230.
 
15) Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaw in periodontal patients with a history of bisphosphonates treatment. J CIin Periodontol 2005;32: 1123-1128.
 
16) Lehrer S, Montazem A, Ramanathan L, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009;67: 159-161.
 
17) Sarasquete ME, Garcia-Sanz R, Marin L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008;112: 2709-2712
 
P.143 掲載の参考文献
1) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000;17: 1-45.
PubMed
2) Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality of following clinical fractures. Osteoporos Int 2000;11: 556-561.
PubMed
3) Johnell O, Kanis JA An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17: 1726-1733.
PubMed
4) Borgstrom F, Strom O, Coelho J, et al. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 2010;21: 495-505.
PubMed
5) Marshall D, Johnell, Wedel H. Meta-analysis of how well measures of bone mineral density predict ocurrence of osteoporotic fractures. BMJ 1996;312: 1254-1259.
 
6) Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007: 18: 1033-1046.
PubMed
7) 菊地克久, 今井晋二. 骨質の評価. リウマチ病セミナーXIX (七川歡次監修). 2008, p89-100, 大阪, 永井書店.
 
8) Beck TJ, Looker AC, Ruff CB, et al. Structural trends in the aging femoral neck and proximal shaft; analysis of the third national health and nutrition examination survey dural-energy X-ray absorptiometry data J Bone Miner Res 2000;15: 2297-2304.
 
9) Greenspan SL, Thomas JB, Resnick NM, et al. Effect of hormone replacernent, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind placebo-controlled clinical trial. J Bone Miner Res 2005;20: 1525-1532.
PubMed
10) Ito M, Ikeda K, Nishiguchi M, et al. Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk. J Bone Miner Res 2005;20: 1828-1836.
 
11) 今井晋二, 高田政彦, 菊地克久, ら. 骨粗鬆症患者腰椎における高解像度3D-CTによる骨梁構造解析-骨粗鬆症患者の「骨質」は診断できるのか? -Osteoporosis Jpn 2005;13: 27-31.
 
12) Chestnut CH III, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging;results from the QUEST study. J Bone Miner Res 2005;20 : 548-1561.
 
13) 骨粗鬆症の予防と治療のガイドライン作成委員会. 骨粗鬆症の予防と治療のガイドライン2006年版. ライフサイエンス出版;2006.
 
14) Shidara K, Inaba M, Okuno S, et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Caltif Tissue Int 2008;82: 278-287.
PubMed
15) Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004: 34: 195-202.
PubMed
16) Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20: 1185-1194.
PubMed
17) Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312: 1254-1259.
PubMed
18) Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739.
PubMed
19) Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: ameta-analysis. Bone 2004: 35: 1029-1037.
 
20) Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005: 16: 155-162.
 
21) Kanis JA, Johansson H, Johnell O, et al. AIcohol intake as a risk factor for fracture. Osteoporos Int 2005: 16: 737-742.
 
22) De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005;16: 1330-1338.
 
23) Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of post-menopausal osteoporosis. Endocr Rev 2002;23: 552-559.
PubMed
24) Bischoff-Ferrari, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291: 1999-2006.
 
25) Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19: 893-899.
 
26) Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005;23: 105-109.
PubMed
27) Moayyeri A. The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol 2008;18: 827-835.
PubMed
28) Petronijevic M, Petronijevic N, Ivkovic M, et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone 2008;42: 582-590.
PubMed
29) Mussolino ME. Depression and hip fracture risk: the NHANES I epidemiologic follow-up study. Public Health Rep 2005;120: 71-75.
PubMed
30) Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16: 581-589.
PubMed
31) Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model Of the WHO fracture risk assessment tool (FRAXTM) . Osteoporos Int 2008;19: 429-425.
 
32) Tosteson AN, Melton III LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19: 437-447.
 

検査,評価

P.150 掲載の参考文献
1) 玉腰暁子. 生活習慣・生活様式の測定方法. 生活習慣病予防マニュアル (大野良之, 柳川洋編). 2005, p83-88, 東京, 南山堂.
 
2) 玉腰暁子. 健康度の測定方法, 生活習慣病予防マニュアル (大野良之, 柳川洋編). 2005, p64, 東京, 南山堂.
 
3) 徳留信寛 (監訳). 食事評価法マニュアル. 1997, 東京, 医歯薬出版株式会社.
 
4) BDHQ・DHQ東大佐々木式食習慣アセスメント / 栄養解析ツールDHQBOX EBN JAPAN. http://www.ebnjapan.org/index.html
 
5) 喫煙と健康-喫煙と健康問題に関する検討会報告書. 2002, 東京, 保健同人社.
 
6) 中村正和, 増居志津子, 大島 明. 個別健康教育禁煙サポートマニュアル. 2002, 東京, 法研.
 
7) 川上憲人. TDSスコア. 治療 2006;88: 2491-2497.
Medical*Online
8) 斉藤 学, 高木 敏 (編). アルコール臨床ハンドブック. 1982, 東京, 金剛出版.
 
9) 北村俊則. 精神症状測定の理論と実際. 1988, 東京, 海鳴社.
 
10) SF-36. http://www.sf-36.jp/
 
11) 池上直己, 福原俊一, 下妻晃二郎, ら. 臨床のためのQOL評価ハンドブック. 2002, 東京, 医学書院.
 
12) 川合眞一. 慢性関節リウマチのQOL医学のあゆみ 1997;182: 616-620.
 
13) 特定非営利活動法人 (NPO) 健康医療評価研究機構 iHope International. http://www.i-hope.jp/
 
14) リウマチe-ネット ガイドライン・診断基準集. http://www.riumachi.Jp/dotor/doc3/kijun/html/ kijun_top.html
 
P.157 掲載の参考文献
1) Chen CH, Yu DT, Chou CT. Biomarkers in spondyloarthropathies. Adv Exp Med Biol 2009;649: 122-132.
PubMed
2) Burrage PS, Mix KS, Brinckerhoff CE, et al. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11: 529-543.
PubMed
3) Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994;53: 768-772.
PubMed
4) Kobayashi A, Naito S, Enomoto H, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 2007;131: 563-570.
PubMed
5) 土岐尋江, 桃原茂樹: 関節リウマチの早期診断のためのMMP-3. リウマチ科 2008;39: 198-203.
 
6) Genevay S, Finckh A, Mezin F, et al. Influence of cytokine inhibitors on concentration and activity of MMP-1 and MMP-3 in disc herniation. Arthritis Res Ther 2009;11: R169.
PubMed
7) Manicourt DH, Fujimoto N, Obata K, et al. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995; 38: 1031-1039.
 
8) Ribbens C, Martin y Porras M, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61: 161-166.
PubMed
9) Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26: 251-258.
PubMed
10) Ates A, TUrkcapar N, Tiryaki O, et al. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol Int 2007;27: 715-722.
PubMed
11) Ribbens C, Andre B, Jaspar JM, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27: 888-893.
PubMed
12) Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43: 852-858.
PubMed
13) Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42: 83-88.
PubMed
14) Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease ac tivity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62: 1094-1099.
 
15) Young-Min S, Cawston T, Marshall N, et al. Biomarkers predlict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56: 3236-3247.
PubMed
16) Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008;10: R106.
PubMed
17) van der Heijde D, Landewe R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005;52: 1979-1985.
PubMed
18) Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthrits Rheum 2004;50: 2942-2953.
 
19) Park JB, Kong CG, Suhl KH, et al. The increased expression of matrix metalloproteinases associated with elastin degradation and fibrosis of the ligamentum flavum in patients with lumbar spinal stenosis. Clin Orthop Surg 2009: 1: 81-89.
PubMed
20) Maksymowych WP. Etiology, pathogenesis and pathology of ankylising spondylitis In Rheumatology 4th ed, Eds by Hochberg MC, Silman AJ, and Smolen JS, et al, Mosby, 2007, Spain, pp 1115-1129.
 
21) Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005: 32: 1911-1917.
PubMed
22) Chen CH, Lin KC, Yu DT, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006: 45: 414-420.
PubMed
23) Maksymowych WP, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56: 1846-1853.
PubMed
24) Maksymowych WP, Rahman P, Shojania K, et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008;35: 2030-2037.
PubMed
25) Woo JH, Lee HJ, Sung IH, et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007;34: 1753-1759.
PubMed
26) Appel H, Janssen L, Listing J, et al. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008;10: R125.
PubMed
27) Wendling D, Cedoz JP, Racadot E. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. Joint Bone Spine 2008;75: 559-562.
PubMed
28) Romero-Sanchez C, Robinson WH, Tomooka BH, et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008;27: 1429-1435.
PubMed
29) Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospec tive observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29: 959-965
 

生物学的反応

P.163 掲載の参考文献
1) Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women: atwin study. J Rheumatol 1996: 23: 1221-1226.
 
2) Toda Y, Toda T, Takemura S, et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998;25: 2181-2186.
 
3) Gabay O, Hall DJ, Berenbaum F, et al. Osteoarthritis and obesity: experimental models. Joint Bone Spine 2008: 75: 675-679.
PubMed
4) Tanko LB, Sondergaard BC, Oestergaard S, et al. An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage. Climacteric 2008;11: 4-16.
PubMed
5) Dumond H, Presle N, Terlain B, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003: 48: 3118-3129.
PubMed
6) Van Beuningen HM, Glansbeek HL, Van der Kraan PM, et al. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-beta injections. Osteoarthritis Cartnage 2000;8: 25-33.
PubMed
7) Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002: 8: 731-737.
PubMed
8) Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277: 37487-37491.
 
9) Lago R, Gomez R, Otero M, et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 2008; 16: 1101-llO9.
 
10) Gosset M, Berenbaum F, Salvat C, et al. Crucial role of Visfatin/PBEF in matrix degradation and PGE2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 2008;58: 1399-1409.
 
11) Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001: 409: 307-312.
PubMed
12) Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. . J Immunol 2005;174: 5789-5795.
PubMed
13) Ushiyama T, Ueyama H, Inoue K, et al. Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. Osteoarthritis Cartilage 1999;7: 560-566.
PubMed
14) Ham KD, Loeser RF, Lindgren BR, et al. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002: 46: 1956-1964.
PubMed
P.168 掲載の参考文献
1) 日本リウマチ学会 (編). リウマチ性疾患の歴史. リウマチ入門 第11版 第1章. 1999.
 
2) 日野原重明, 仁木久恵 (訳). 「プラトンが描いた医術と医師」 平静の心. オスラー博士講演集, 2000, 東京, 医学書院
 
3) 志水正敏. ストレスと慢性関節リウマチ. リウマチ病セミナーIX (七川歡次監修), 1998, p31-37, 大阪, 永井書店.
 
4) Boscarino JA, Forsberg CW, Goldberg J. A twin study of the association between PTSD symptoms and rheumatoid arthritis. Psychosom Med 2010;72: 481-486.
 
5) Gouin JP, Hantsoo L, Kiecolt-Glaser JK. Immune dysregulation and chronic stress among older adults: a review. Neuroimmunomodulation 2008;15: 251-259.
PubMed
6) Kiecolt-Glaser JK, Heffner KL, Glaser R, et al. How stress and anxiety can alter immediate and late phase skin test responses in allergic rhinitis. Psychoneuroendocrinology 2009;34: 670-680.
PubMed
7) Barsky AJ and Borus JF. Functional Somatic Syndromes. Ann Intern Med 1999;130: 910-921.
PubMed
8) 志水正敏. リウマチ患者に多い訴えとその対策. リウマチ病セミナーXIX (七川歡次監修), 2008, p151-158, 大阪, 永井書店
 
9) Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet 1999: 354: 936-939.
PubMed
10) Garcia-Campayo J, Fayed N, Serrano-Blanco A, et al. Brain dysfunction behirld functional symptoms: neuroimaging and somatoform, conversive, and dissociative disorders. Curr Opin Psychiatry 2009: 22: 224-231.
PubMed
11) Ushida T, Ikemoto T, Taniguchi S, et al. Virtual pain stimulation of allodynia patients activates cortical representation of pain and emotions: a functional MRI study. Brain Topogr 2005;18: 27-35.
PubMed
12) Ushida T, Ikemoto T, Tanaka S, et al. Virtual needle pain stimuli activates cortical representation of emotions in normal volunteers. Neurosci Lett 2008;439: 7-12.
PubMed
13) Kuchinad A, Schweinhardt P, Seminowicz DA, et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 2007;27: 4004-4007.
 
14) Emad Y, Ragab Y, Zeinhom F, et al. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 2008;35: 1371-1377.
PubMed
15) Fayed N, Garcia-Campayo J, Magallon R, et al. Localized lH-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 2010;12: R134.
 
16) Chen JJ, Wang JY, Chang YM, et al. Regional cerebral blood flow between primary and concomitant fibromyalgia patients: a possible way to differentiate concomitant fibromyalgia from the primary disease. Scand J Rheumatol 2007;36: 226-232.
PubMed
17) Moldofsky H. Rheumatic manifestations of sleep disorders. Curr Opin Rheumatol 2010;22: 59-63.
PubMed
18) Moldofsky H, Scarisbrick P, England R, et al. Musculosketal symptoms and non-REM sleep distur bance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975;37: 341-351.
 
19) Hirsch M, Carlander B, Vergo M, et al. Objective and subjective sleep disturbances in patients with rheumatoid arthritis. A reappraisal. Arthritis Rheum 1994;37: 41-9.
 
20) Lee YC, Chibnik LB, Lu B, Wasan AD, et al. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: across-sectional study. Arthritis Res Ther 2009;11.
 
21) McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. Arthritis Rheum 1995;38: 826-834.
PubMed
22) Chandrasekhara PK, Jayachandran NV, Rajasekhar L, et al. The prevalence and associations of sleep disturbances in patients with systemic lupus erythematosus. Mod Rheumatol 2009: 19: 407-415.
 
23) Lorton D, Lubahn CL, Estus C, et al. Bidirectional communication between the brain and the immune system: implications for physiological sleep and disorders with disrupted sleep. Neuroimmunomodulation 2006: 13: 357-374.
PubMed
24) 吉田善章. 自然のしくみと非線形科学. 第19回近畿リウマチ病研究会講演集, p33-38, 2010.
 
25) 長谷川 晃. エントロピーの法則と生命現象. 第20回近畿リウマチ病研究会講演集, p57-62, 2010.
 
26) Hasegawa A. Optical soliton in dielectric fibers and self-organization of turbulence in plasmas in magnetic fields. Proc Jpn Acad Ser B Phys Biol Sci 2009;85: 1-11.
PubMed
P.175 掲載の参考文献
1) Teitelbaum SL: Bone resorption by osteoclasts. Science 2000;289: 1504-1508.
PubMed
2) Teitelbaum SL, Ross FP: Genetic regu lation of osteoclast development and function. Nat Rev Genet 2003;4: 638-649.
 
3) Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7: 292-304.
PubMed
4) Lorenzo J, Horowitz M, Choi Y: Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008;29: 403-440.
PubMed
5) Goeppert-Mayer M: Uber Elementarakte mit zwei Quantensprungen Ann Phys 1931: 9: 273-295.
 
6) Denk W, Strickler JH, Webb WW: Two-photon laser scanning fluorescence microscopy. Science. 1990; 248: 73-76.
PubMed
7) Denk W, Svoboda K: Photon upmanship: why multiphoton imaging is more than a gimmick Neuron 1997;18: 351-357.
PubMed
8) Helmchen F, Denk W: Deep tissue two-photon microscopy. Nat Methods 2005: 2: 932-940.
PubMed
9) Takahashi N, Kasai H: Exocytic process analyzed with two-photon excitation imaging in endocrine pancreas. Endocr J 2007;54: 337-346.
PubMed
10) Takahashi N, Kishimoto T, Nemoto T, et al: Fusion pore dynamics and insulin granule exocytosis in the pancreatic islet. Science 2002;297: 1349-52.
PubMed
11) Huang AY, Qi H, Germain RN: Illuminating the landscape of in vivo immunity: insights from dynamic in situ imaging of secondary lymphoid tissues. Immunity 21: 331-339, 2004.
PubMed
12) Stoll S, Delon J, Brotz TM, et al: Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296: 1873-1876, 2002.
PubMed
13) Miller MJ, Wei SH, Parker I, et al: Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002;296: 1869-1873.
PubMed
14) Bousso P, Bhakta NR, Lewis RS, et al: Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science 2002;296: 18676-1880.
 
15) von Andrian UH: Immunology. T cell activation in six dimensions. Science 2002: 296: 1815-1817.
PubMed
16) Germain RN, Bajenoff M, Castellino F, et al: Making friends in out-of-the-way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev 2008;221: 163-181.
PubMed
17) Ishii M, Egen JG, Klauschen F, et al: Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009: 458: 524-528.
PubMed
18) Matloubian M, Lo CG, Cinamon G, et al: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S l P receptor 1. Nature 2004;427: 355-360.
 
19) Mandala S, Hajdu R, Bergstrom J, et al: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296: 346-349.
PubMed
20) Kappos L, Antel J, Comi G, et al: on behalf of the FTY720 D2201 Study Group. : Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006: 355: 1124-1140.
 
21) Kikuta J, Iwai K, Saeki Y, et alal: SlP - targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol. Int, in press.
 

治療と副作用

P.182 掲載の参考文献
1) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Wallis RS. Lancet Infect Dis. 2008;8: 601-611.
PubMed
2) Carrnona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al, BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52: 1766-1772.
 
3) Koike R, Takeuchi T, Eguchi K, et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Japan College of Rheumatology. Mod Rheurnatol 2007;17: 451-458.
PubMed
4) Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67: 189-194.
PubMed
5) Nagabhushanam V, Solache A, Ting LM, et al. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 2003;171: 4750-4757.
 
6) Ogata A, Mori M, Hashimoto S, et al. Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol 2010;20: 130-133.
PubMed
7) Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20: 222-232.
PubMed
8) Koike R, Harigai M, Atsumi T, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009;19: 351-357.
 
9) McHugh SL, Newton CA, Yamamoto Y, et al. Tumor necrosis factor induces resistance of macrophages to Legionella pneumophila infection. Proc Soc Exp Biol Med 2000;224: 191-196.
PubMed
10) Tubach F, Ravaud P, Salmon-Ceron D, et al: Recherce Axee sur la Tolerance des Biotherapies Group. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006;43: e95-100.
 
P.189 掲載の参考文献
1) Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 1999;354: 1932-1939.
 
2) Takeuchi T, Miyasaka N, Inoue K, et al. RISING study Irnpact of trough serum level on radiographic and clinical response to imfliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009;19: 478-487.
 
3) van der Biji AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007;56: 2129-2134.
 
4) Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302: 875-878.
PubMed
5) KremerJM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthriis Rheum 2009;60: 1895-1905.
PubMed
6) Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nature Immunology 2009; 10: 340-347.
PubMed
7) Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008: 58: 3309-3318.
PubMed
P.195 掲載の参考文献
1) Gillmore JD, Lovat LB, Hawkins PN, et al. Amyloid load and clinical outcome in AA amyloidosis. in relation to circulating concentration of serum arnyloid A protein. Lancet 2001;358: 24-29.
PubMed
2) Gottenberg JE, Merle-Vincent F, Mariette X, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003: 48: 2019-2024.
PubMed
3) Hagihara K, Nishikawa T, Isobe T, et al. IL-6 plays a critical role in synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314: 363-369.
 
4) Hagihara K, Nishikawa K, Sugamata Y, et al. Essential role of STAT3 in cytokine-driven NF-κ B-mediated serum amyloid A gene expression. Gene Cells 2005;10: 1051-1063.
 
5) Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines. cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol l 999: 163: 1521-1528.
 
6) Nishimoto N, Yoshizaki K, Kishimoto T, et al. Treatment of rheumatoid arthritis with humanized antiinterleukin-6 receptor antibody. Arthritis Rheum 2004;50: 1761-1769.
 
7) Nishimoto N , Sasai M , shima Y , et al. Improvement i n Castleman s disease by humanized antiinterleukin-6 receptor antibody therapy, Blood 2000;95, 56-61.
 
8) Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant antiinterleukin-6 receptor antibody in children with systemic onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52: 818-825.
 
9) 吉崎和幸. 抗体製薬を用いたInterleukin 6阻害療法から学んだ自己免疫疾患に対する治療戦略. YAKU-GAKU ZASSHI 2009;129: 661-674.
 
10) Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody tocilizumab. to treat amyroid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54: 2997-3000.
 
11) Nishida S, Hagihara K, Yoshizaki K, et al. Rapid improvement of AA amyloidosis with humanized anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009;68, 1235-1236
 
P.201 掲載の参考文献
1) Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354: 2667-2676.
 
2) Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007: 110: 237-241.
PubMed
3) Classen JF, Henrohn D, Rorsman F, et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009;60: 1137-1144.
PubMed
4) Loizos N, Lariccia L, Weiner J, et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera Arthritis Rheum 2009: 60: 1145-1151.
 
5) Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007: 56: 311-322.
PubMed
6) Ahmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different pre-clinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60: 219-224.
 
7) van Daele PL Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008;58: 2549-2552.
PubMed
8) Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis Arthritis Rheum 2009: 60: 584-591.
PubMed
9) Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009;114: 719-722.
PubMed
10) Terabe F, Kitano M, Ogata A et al. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Mod Rheumatol 2009;19: 522-529.
 
11) Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116: 2633-2642.
PubMed
12) Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003;35: 362-367.
PubMed
13) Miyachi K, Ihara A, Hankins RW, et al. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia Clin Rheumatol 2003;22: 329-332.
PubMed
14) Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005;115: 2691-2694.
PubMed
15) Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178: 81-88.
PubMed
16) Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experirnental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115: 2811-2821.
PubMed
P.209 掲載の参考文献
1) 井関雅子. 鎮痛補助薬. 日医雑誌 2009: 138: 964-965.
 
2) Salih AM, Gray RE, Mills KR, et al. A clinical, serological and neurophysiological study of restless legs syndrome in rheumatoid arthritis. Br J Rheumatol 1994;33: 60-63.
PubMed
3) 江川 功: restless legs syndrome. リウマチ病セミナーXII (七川勸次監修), 2001, p106-111, 大阪, 永井 書店.
 
4) Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996: 312 : 1339.
PubMed
5) Gudbjornsson B, Broman JE , Hetta J , et al. Sleep disturbances in patients with primary Sjogren's syndrome. Br J Rheumatol 1993;32: 1072-1076.
PubMed
6) Prado GF, Allen RP, Trevisani VM, et al. Sleep disruption in systemic sclerosis (scleroderma) patients: clinical and polysomnographic findings. Sleep Med 2002: 3: 341-345.
PubMed
7) Sivri A, Guler-uysal F. The electroneurophysiologycal evaluation of Rheumatoid arthritis patients. Clin Rheumatol 1998;17: 416-418.
PubMed
8) Dani K, Ramachandran R, Capell HA, et al. Neuropathies in the rheumatoid patient: a case of the heavy hand. Scott Med J 2005;50: 125-126.
 
9) Ma W, Eisenach JC. Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 2003: 121: 691-704.
PubMed
10) Ma W, Chabot JG, Vercautererl F et al. Injured nerve-derived COX2/PGE2 contributes to the maintenance of neuropathic pain in aged rats. Neurobiol Aging 2010: 7: 1227-1237.
 
11) 西林保朗. 線維筋痛症のレゾンデートル-運動疾患患者の全人的ケアへのいざない-. リウマチ病セミナー XIX (七川歡次監修), 2008, p58-67, 大阪, 永井書店.
 
12) Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37: 1593-1601.
PubMed
13) Russell IJ, Vaeroy H, Javors M, et al. Cerebrospainal fluid biogenic amine metabolites in fiberomyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35: 550-556.
PubMed
14) 行岡正雄, 三木健司: 線維筋痛症の病態の把握, 西岡久寿樹編, 線維筋痛症ハンドブック, 2007, p70-81, 東京, 日本医事新報社.
 
15) Luerding R, Weigand T, Bogdahn U, et al. Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: structural correlates of pain Cognition interaction. Brain 2008;131: 3222-331.
PubMed
16) David AW, Richard HG. Biology and therapy of fibromyalgia Functional magnetic resonance imaging findings in fibromyalgia Arthritis Research＆Therapy 2006: 8: 224-232.
 
P.215 掲載の参考文献
1) 松本美富士, 前田伸治, 玉腰暁子. 線維筋痛症の臨床疫学像 (全国疫学調査の結果から). 臨床リウマチ 2006;18: 87-92.
 
2) 松本美富士, 線維筋痛症ハンドブック (西岡久寿樹編), 第3章疫学・病態 (1) 線維筋痛症の疫学, 2007, p56-69, 東京, 日本医事新報社.
 
3) Arnold LM, Goldenberg DL, Stanford SB et al. Gabapentin in the Treatment of Fbromyalgia: A Randomized Double-blind Placebo-controlled, Multicenter trial. Arthritis Rheum 2007;56 (4): 1336-1344.
PubMed
4) 岡 寛, 長田賢一, 西岡久寿樹, ら. 線維筋痛症に対するガバペンチンの効果. 炎症・再生 2008: 28: 363.
 
5) 岡 寛, 西岡久寿樹. リウマチの類縁疾患 線維筋痛症. 綜合臨牀 2008;57: 2916-2920.
 
6) Bennett RM, Kamin M, Karin R, et al. Tramadol and Acetaminophen Combination Tablets in the treatment of Fibromyalgia Pain: Double-Blind, Randornized/Placebo-Controlled Study. Am J Med 2003; 114: 537-545.
 
7) 線維筋痛症診療ガイドライン 2009. 日本線維筋痛症学会編集. 2010. 3. 東京, 日本リウマチ財団.
 
P.221 掲載の参考文献
1) Selter PE Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002;18: 119-124.
 
2) 「ジストニアの疫学, 診断, 治療に関する総合的研究」班編. ジストニアの治療指針と疫学, 治療の現状 2005. 2006年1月.
 
3) 福原俊一, 鈴鴨よしみ. SF-36 v2(TM) 日本語版マニュアル, NPO健康医療評価研究機構, 2004年1月.
 
4) Tarsy D. Comparisom of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 1997: 12: 100-102.
 
5) Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37: 616-623.
PubMed
6) Da Andres J, Cerda-Ormedo G, Valia JC, et al. Use of botulinum toxin in the treatment of chronic myo-fascial pain. Clin J Pain 2003: 19: 269-275.
 
7) Charles E Argoff. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2003;18: S177-S781.
 
8) Vasan CW, Liu WC, Klussmann JP, et al. Botulinum toxin type A for the treatment of chronic neck pain after neck dissection. Head neck 2004;26: 39-45.
PubMed
9) Smuts JA, Schultz D, Barnard A Mechanism of action of botulinum toxin type A in migrane prevention: a pilot study. Headache 2004;44: 801-805.
 
10) Durham PL Cady R, Cady R. Regulation of calcitonin gene-related pepride secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy+commentary. Headache 2004;44: 35-43.
 
11) Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26: 785-793.
PubMed
12) Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management Headache 2003;43: S9-S15.
PubMed
13) Cui Minglei, Khanjou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2007;107: 125-133.
 
14) Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2×3 and TRPV l in suburothelial nerve fibers following intradetrusor injectios of botulinum toxin for human detrusor overactivity. J Urol 2005;174b: 977-829.
 
15) 厚生労働省. 平成16年国民生活基礎調査 第2巻 全国編. 東京, 厚生統計協会 2006.
 
16) Boon AJ, Smith J, Dahm DL, et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R 2010: 2: 268-276.
PubMed
17) Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine 2009;76: 190-194.
PubMed
P.229 掲載の参考文献
1) 浦田幸朋. 免疫抑制患者へのワクチン接種の適応と禁忌-英国のガイドラインを踏まえて-Med Pract 2004;21: 332-334.
Medical*Online
2) 小橋川 剛, 田中栄一, 井上英介, ら. 関節リウマチ (RA) 患者におけるインフルエンザワクチンの有用性-IORRAコホートにおける検討. 日本リウマチ学会誌 2009;53: 346.
 
3) 都留智巳, 洲崎みどり, 吉尾直子, ら. トシリズマブによるIL-6阻害治療中の関節リウマチ患者におけるインフルエンザワクチンに対する免疫反応の検討- DMARDs 治療中の関節リウマチ患者との比較-
 
4) 山内勇人, 大西 誠: 関節リウマチ患者におけるインフルエンザワクチン接種による抗体産生能に関する検討. 感染症学雑誌 2007: 51: 500-501.
 
5) 眞柴晃一, 小島武士, 大塚 毅,ら. 関節リウマチ患者におけるインフルエンザワクチン接種の血清学的検討. 感染症学 2006;80: 749.
 
6) 杉本和則, 林 正岳, 勝尾信一, ら. 関節リウマチ患者におけるインフルエンザワクチンの有効性と安全性. 日本リウマチ学会誌 2006;50th-15th: 291.
 
7) 窪田哲朗, 新居登紀子. 抗TNF製剤は関節リウマチ患者のインフルエンザワクチンに対する応答性を減弱させない. リウマチ科 2007;38: 247-251.
 
8) 都留智巳. トシリズマブ投与下における関節リウマチ患者のインフルエンザワクチン接種に対する免疫反応に関する研究. 平成19年度総括・分担研究報告書 2008;80-84.
 
9) Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67: 713-716.
PubMed
10) Kaine JL, Kivitz AJ, Birbara C, et al. Immune response following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-279.
PubMed
11) Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatol 2007;46: 608-611.
 
12) Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65: 191-194.
PubMed
13) Elkayam O: Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Develop Immunol 2006: 13: 349-351.
 
14) 都留智巳: トシリズマブにて治療中の関節リウマチ患者における23価肺炎球菌ワクチンに対する免疫反応に関する研究. 平成19年度総括・分担研究報告書 2008;85-88.
 
15) Elkayam O, Ablin J, Caspi D: Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 2007;6: 312-314.
PubMed
16) Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving nfliximab plus methotrexate or methotrexate alone. J Rehumatol 2007; 34: 952-957.
PubMed
17) Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatol 2006: 45: 106-111.
 
18) 渡辺 徹,阿部時也, 小田良彦, ら. インフルエンザワクチン接種後に発症した, 抗リン脂質抗体陽性のHenoch-Schonlein紫斑病の1例 新潟医学会雑誌 2002;116: 184.
Medical*Online
19) Korematsu S, Miyahara H, Kawano T, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period Vaccine 2009;27: 5041-5042.
 
20) 大石 勉, 冠木智之, 田中理砂, ら. 免疫抑制薬を使用している小児リウマチ性疾患患児 (若年性特発性関節炎, 全身性紅斑性狼瘡, 皮膚筋炎, 混合性結合織病) に対するインフルエンザワクチンの免疫原性, 安全性の検討. 埼玉県医学会雑誌 2009: 43: 443-448.
 
21) Malleson PN, Tekano JL, Scheifele DW, et al. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993;20: 1769-1773.
PubMed
22) McCann LJ. Should children under treatment for juvenile idiopathic arthritis receive flu vaccination? Arch Dis Childhood 2007;92: 366-368.
 
23) Zonneveld-Huijssoon E, Ronaghy A, VanRossum MA, et al. Safety and efficacy of menigococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 2007;56: 639-646.
 
24) Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007;66: 1384-1387.
PubMed
25) Kasapcopur O, Cullu F, Kamburodlu-Goksel A, etc. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004: 63: 1128-1130.
 
26) Korematsu S, Miyahara H, Kawano T, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period
 
27) 佐藤恵美, 坂井博之, 高橋英俊, ら. インフルエンザワクチンを契機に発症した成人Still病の1例. 臨皮 2001;55: 876-879.
 
28) 松山 毅, 前田基晴. 小児リウマチ性疾患の病態と長期管理 小児リウマチ性疾患患児への予防接種の実際. 小児内科 2001;33: 853-856.
 
29) Kato T, Kiire A, Yamagata H, et al. Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections. Mod Rheumatol 2006;16: 327-329.
 
30) 舌津高秋, 中村尚子, 野倉一也, ら. インフルエンザと神経障害インフルエンザワクチン接種後の中枢神経障害 (ADEM). 神経内科 2004;60: 139-146.
 
31) 村上修一, 石川 肇, 遠山知香子, ら. インフルエンザ予防接種後に間質性肺炎が増悪し死亡した慢性関節リウマチの一例. 新潟医学会雑誌 2002;116: 184-185.
Medical*Online
32) Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) . Clin Develop Immunol 2006;13: 373-375.
 
33) Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Vaccines 2008;46: 1459-1465.
PubMed
34) Ravikumar R, Anolik J, Looney J. Vaccine responses in patients with rheumatoid arthritis. Curr Rheumatol Rep 9: 407-415, 2007
 
35) Winthrop KL. Serious infections with antirheumatic therapy: are biologicals worse? Ann Rheum Dis 2006;65 Suppl 3: iii54-57.
 
36) Koutsogeorgopoulou L, Antoniadis C, Vassilopoulos D, et al. Preventive influenza vaccination for patients with rheumatoid arthritis. A need for an international campaign. Clin Rheumatol 2009: 28: 103-104.
PubMed

手術

P.242 掲載の参考文献
1) Nanno M, William L. Buford Jr WL, Patterson RM, et al. Three-Dimensional Analysis of the Ligamentous Attachments of the First Carpometacarpal Joint. J Hand Surg 2006;31A: 1160-1170.
 
2) Varley GW, Calvey J, Hunter JB, et al. Excision of the trapezium for osteoarthritis at the base of the thumb. J Bone Joint Surg 1994: 76B: 964-968.
 
3) Dhar S, Gray ICM, Jones WA, et al. Simple excision of the trapezium for osteoarthritis of the carpometacarpal joint of the thumb. J Hand Surg 1994;19B: 485-488.
 
4) Vandenbroucke J, De Schrijver F, De Smet L, et al. Simple trapezectomy for treatment of trapeziome-tacarpal osteoarthritis of the thumb. Clin Rheumatol 1997;16: 239-242.
PubMed
5) Saffar F. Arthritis of the base of the thumb. IN: Tubiana R, editor. 'The Hand' Vol. V, Philadelphia: SAUNDERS Co;1999: 395-408.
 
6) Davis TRC, Brady O, Dias JJ. Excision of the Trapezium for Osteoarthritis of the Trapeziometacarpal Joint: AStudy of the Benefit of Ligament Reconstruction or Tendon Interposition. J Hand Surg 2004;29A: 1069-1077.
 
7) Kriegs-Au G, Petje G, Fojtl E, et al. Ligament Reconstruction with or without Tendon Interposition to Treat Primary Thumb Carpometacarpal Osteoarthritis. J Bone Joint Surg 2004;86A: 209-218.
 
8) Hofammann DY, Ferlic DC, Clayton ML. Arthroplasty of the Basal Joint of the Thumb Using a Silicone Prosthesis. Long-term follow-up. J Bone Joint Surg 1987;69A: 993-997.
 
9) Nicholas RM, Calderwood JW. De la Caffiniere Arthroplasty for Basal Thumb Joint Osteoarthritis. J Bone Joint Surg 1992: 74B: 309-312.
 
10) Ferrari B, Steffee AD. Trapeziometacarpal total joint replacement using the Steffee prosthesis. J Bone Joint Surg 1986;68A: 1177-1184.
 
11) Hartigan BJ, Stern PJ, Kiefhaber TR. Thumb Carpometacarpal Osteoarthritis: Arthrodesis Compared with Ligament Reconstruction and Tendon Interposition. J Bone Joint Surg 2001;83A: 1470-1478.
 
12) Menon J. Arthroscopic management of trapeziometacarpal joint arthritis of the thumb. Arthroscopy 1996;12: 581-587.
PubMed
13) Slutsky DJ. The use of a dorsal-distal portal in trapeziometacarpal arthroscopy. Arthroscopy 2007; 23: 1244. e1-1244. e4.
 
14) Hofmeister EP, Leak RS, Culp RW, et al. Arthroscopic hemitrapeziectomy for first carpometacarpal arthritis: results at 7-year follow-up. Hand 2009: 4: 24-28.
PubMed
15) Nalebuff EA. The rheumatoid thumb. Clin Rheum Dis 1984;10: 589-609.
PubMed
16) Burton RI. Basal joint arthritis. Fusion, implant, or soft tissue reconstruction? Orthop Clin North Am 1986: 17: 493-503.
PubMed

書評

最近チェックした商品履歴

Loading...